Rachid Izzar - Dec 2, 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Alzheimer's Disease
Signature
/s/ Wendell Taylor, attorney-in-fact for Rachid Izzar
Stock symbol
BIIB
Transactions as of
Dec 2, 2022
Transactions value $
-$226,865
Form type
4
Date filed
12/6/2022, 05:37 PM
Previous filing
Jul 6, 2022
Next filing
Jan 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +1.29K +60.9% $0.00 3.4K Dec 2, 2022 Direct
transaction BIIB Common Stock Tax liability -$170K -570 -16.79% $298.90 2.83K Dec 2, 2022 Direct
transaction BIIB Common Stock Options Exercise $0 +425 +15.04% $0.00 3.25K Dec 2, 2022 Direct
transaction BIIB Common Stock Tax liability -$56.5K -189 -5.82% $298.90 3.06K Dec 2, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -1.29K -100% $0.00* 0 Dec 2, 2022 Common Stock 1.29K $0.00 Direct F1
transaction BIIB Restricted Stock Unit Options Exercise $0 -425 -49.53% $0.00 433 Dec 2, 2022 Common Stock 425 $0.00 Direct F2
transaction BIIB Restricted Stock Unit Other $0 -433 -100% $0.00* 0 Dec 2, 2022 Common Stock 433 $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award was granted to the reporting person on December 2, 2019, and vested in full on December 2, 2022.
F2 This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.